Odyssey Therapeutics Inc ODTX
News
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
